Chembio Wins $13.2M US BARDA Contract To Develop POC Zika Tests

HHS and its subagency Biomedical Advanced Research and Development Authority (BARDA) has put together additional funding to award Chembio Diagnostic Systems $13.2m to develop and commercialize the firm's rapid point-of-care Zika test, a mere two weeks after the agency said it only had enough funds for Zika vaccine development.

Chembio Diagnostics Inc. announced on Aug. 25 a fresh, $13.2m total contract from BARDA, HHS's Biomedical Advanced Research and Development Authority, so it can carry out development and commercialization of its rapid point-of-care Zika test, although in mid-August HHS Secretary Sylvia Burwell was concerned about finding an additional $342m to support diagnostics development to help pinpoint suspected cases in the US. (Also see "Hologic Wins $4.1m To Advance Zika Blood Screen" - Medtech Insight, 15 August, 2016.)

Chembio plans to use an initial $5.9m allotment from BARDA to work on its DPP Zika IgM/IgG Assay and DPP...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

FDA Outlines Responsibilities For Owners Of Transferred 510(k)s

 
• By 

The US FDA's new draft guidance details the responsibilities of new owners of 510(k) clearances, including making timely updates device listings in FURLS and GUDID to maintain accurate information for safety alerts and recalls. Comments on the draft are accepted until 4 August.

US House Budget Sets FDA FY26 Funding At $3.2B

 

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.

Panel: FDA’s Home Healthcare Initiative Holds Promise, But Challenges Remain

 
• By 

During a recent FDLI panel, experts discussed the FDA's Home Healthcare initiative, highlighting its potential benefits and challenges. Key issues include usability testing, reimbursement, labeling for home use, and the need for innovation while ensuring patient safety.

J&J MedTech Launches KINCISE 2 Surgical Automated System In US

 

The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.

More from North America

Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation

 

Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.

‘Dawn Of FDA’s AI Era’ Has Arrived. Makary Announces Early Implentation Of ‘Elsa’ Platform

 

US FDA Commissioner Marty Makary says the agency’s generative AI tool ‘Elsa’ will allow employees across the FDA to work more efficiently. The commissioner says Elsa’s launch comes ahead of schedule following a successful pilot program.

DeepLook AI Imaging Provides A Deeper Look At Dense Breast

 

DeepLook Medical recently announced the commercial rollout of DL Precise, an AI-powered imaging platform that enhances breast cancer screening, at major healthcare institutions across the US.